Navigation Links
New study: Incidence and mortality of PCa after termination of PSA-based screening
Date:3/18/2013

Milan, 15 March 2013 - Men who participate in biennial PSA based screening have a lower risk of being diagnosed as well as dying from prostate cancer up to 9 years after their last PSA test, according to the results of a new study to be presented at the 28th Annual EAU Congress in Milan

A joint Swedish-UK study aimed to examined the risk of developing prostate cancer after last invitation to screening. This investigation follows up on previous publication from the Gteborg randomized screening trial (part of ERSPC) by the same group which showed that biennial PSA screening lowered PC mortality with 44%

In the course of the study, which launched in 1995, 20000 men were randomized and 9 952 have been invited every second year for PSA testing while 9952 were randomized to a control arm. All cases of prostate cancer in the screening (n= 6449) as well as the control arm (n= 6974) after reaching the upper age limit for invitation (median 69 range 67-71 years) were identified by matching with the Regional Cancer Register in western Sweden.

For all deaths in men with prostate cancer, a review of cause of death was performed by an independent committee, the date of follow-up being 30 June 2012 or at a maximum of 12 years. PCs diagnosed were classified into low, intermediate or high/advanced risk groups and all attendees were defined as participating at least once

In the course of the study, a total of 173 men with were diagnosed with prostate cancer in the invited arm (with a median follow-up of 4.8 years) and 371 were diagnosed in the control arm (with a median follow-up of 4.9 years).

Up to 9 years after last invitation all risk groups were more commonly diagnosed in the control arm but after 9 years the rates in the screening arm caught up, other than those for the low risk group. In the invited arm, non-attendees had an incidence similar to that of the control arm. Also mortality in PC was lower in the screening arm up to 9 years, which is approximately 50 % of that in the control arm, after termination of screening. At the same time, in the interval of 9-12 years, the screening group had a similar mortality rate to the control.


'/>"/>

Contact: Ivanka Moerkerken
i.moerkerken@uroweb.org
31-026-389-0680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Study: Smoking Increases HPV Risks; polyDNA Recommends Gene-Eden-VIR Against HPV
2. Omega XL Reports New Independent Study: Omega-3s Can Boost Children’s IQ
3. Study: 15% of Children Ages 10 - 14 Consider Using Steroids; polyDNA Recommends Muxscle for Safe Muscle Building
4. Study: Dynamic new software improves care of aging brain
5. Bel Marra Health Reports on a New Study: Female Obesity Could Be Due to Less Participation in Household Tasks
6. Study: Steroid Abuse in Teens is Increasing; polyDNA Recommends Muxscle for Safe Muscle Building
7. Study: Catheter-based varicose vein treatments more cost-effective
8. Penn study: Financial incentives affect prostate cancer treatment patterns
9. Study: Mega Vitamins Wont Help After Heart Attack, Chelation Treatment Might
10. Study: Diabetic medication may protect patients from developing heart failure
11. Doctors Health Press Reports on German Study: Only 20% of Patients Get Colonoscopies, Important in Preventing and Diagnosing Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... 23, 2017 , ... TSC Advantage has been awarded Gold ... Solution Innovations and Security Solution for Government Innovations. Both gold awards recognize TSC ... DHS SAFETY Act-designated enterprise security assessment approach. , The ninth annual Golden Bridge ...
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... August 22, 2017 , ... Each of the past six years, Lightning Labels has ... of these labels and stickers, demonstrating the variety and creativity of their designs. Submissions this ... images came in. Now, it's time to announce the winners of the sixth annual Photo ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a captivating and romantic ... Edward Koontz. “To Walk Away” is the creation of published author, Larry R. Sherman, ... hundred manuscripts in chemistry and religion, as well as four novels. , Though ...
(Date:8/22/2017)... ... , ... “Glimpses Of Light”: is a unique and thought inspiring guide ... creation of published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author ... , Shepherd shares, “Love is one of the least understood and yet most sought-after ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... EWING, N.J. , Aug. 17, 2017 Bio-Ess Laboratories, LLC ... to increase antibody titer and present new data on Cell-Ess® ... in Boston, MA August 21-25.  The Bioprocessing ... for today,s bioprocess challenges. ... Boost and Optimizer ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
Breaking Medicine Technology: